Polycystic ovary syndrome and hyperprolactinemia are distinct entities

References

• Slowey M J. Polycystic ovary syndrome: new perspective on an old problem. South Med J 2001; 94: 190–196
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo R A. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999; 84: 1897–1899
   PubMed Web of Science ®Google Scholar
• Sharma A, Atiomo W. Recent developments in polycystic ovary syndrome. Curr Obstet Gynaecol 2003; 13: 281–286
   Google Scholar
• Panidis D K, Rousso D H, Matalliotakis I M, Kourtis A I, Vlassis G D, Koumantakis E E. Hyperinsulinemia does not influence androgens/estrogens ratio in patients with polycystic ovary syndrome. Int Fertil Womens Med 1999; 44: 301–306
   PubMedGoogle Scholar
• Legro R S, Gnatuk C L, Kunselman A R, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 2005; 90: 3236–3242
   PubMed Web of Science ®Google Scholar
• Yen S SC. The polycystic ovary syndrome. Clin Endocrinol (Oxf) 1980; 12: 207–208
   Google Scholar
• Hull M GR. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol 1987; 1: 235–245
   PubMedGoogle Scholar
• Franks S. Polycystic ovary syndrome. N Eng J Med 1995; 333: 853–861
   PubMed Web of Science ®Google Scholar
• Motta L DC, Motta L ACR. Síndrome dos ovários policísticos. J Bras Ginecol 1999; 109: 3–8
   Google Scholar
• Motta L DC, Motta L ACR. Síndrome dos ovários policísticos: fisiopatologia e tratamento. Brasilia Med 2000; 37: 31–37
   Google Scholar
• Buvat J, Herbaut M B, Marcolin G, Racadot A, Fourlinnie J C, Beuscart R, Fossati P. A double blind controlled study of the hormonal and clinical effects of bromocriptine in the polycystic ovary syndrome. J Clin Endocrinol Metab 1986; 63: 119–124
   PubMedGoogle Scholar
• Parsanezhad M E, Alborzi S, Jahromi B N. A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptine in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level. Int J Fertil Womens Med 2002; 47: 272–277
   PubMedGoogle Scholar
• Zacur H A, Foster G V. Hyperprolactinemia and polycystic ovary syndrome. Semin Reprod Endocrinol 1992; 10: 236–242
   Google Scholar
• Leblanc H, Lachelin G C, Abu-Fadil S, Yen S SC. Effect of dopamine infusion on pituitary hormone secretion in humans. J Clin Endocrinol Metab 1976; 43: 668–735
   PubMed Web of Science ®Google Scholar
• Quigley M E, Rakoff J S, Yen S SC. Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome. J Clin Endocrinol Metab 1981; 52: 231–234
   PubMed Web of Science ®Google Scholar
• Franks S. Polycystic ovary syndrome: a changing perspective. Clin Endocrinol (Oxf) 1989; 31: 87–120
   PubMed Web of Science ®Google Scholar
• Barnes R B, Lobo R A. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation. J Clin Endocrinol Metab 1985; 61: 779–782
   PubMed Web of Science ®Google Scholar
• Steingold K A, Lobo R A, Judd H L. The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovary syndrome. J Clin Endocrinol Metab 1986; 62: 1048–1051
   PubMedGoogle Scholar
• Bahceci M, Tuzcu A, Canoruc N, Tuzun Y, Kidir V, Aslan C. Serum C-reactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance. Horm Res 2004; 62: 283–287
   PubMed Web of Science ®Google Scholar
• Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and cell β function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412–419
   PubMed Web of Science ®Google Scholar
• Venturoli S, Porcu E, Fabbri R, Magrini O, Paradisi R, Pallotti G, Gammi L, Flamigni C. Postmenarchal evolution of endocrine pattern and ovarian aspect in adolescents with menstrual irregularities. Fertil Steril 1987; 48: 78–85
   PubMed Web of Science ®Google Scholar
• Szilagyi A, Hole R, Keckstein J, Rossmanith W G. Effects of ovarian surgery on the dopaminergic and opioidergic control of gonadotropin and prolactin secretion in women with polycystic ovarian disease. Gynecol Endocrinol 1993; 7: 159–166
   PubMed Web of Science ®Google Scholar
• Laatikainen T, Tulenheimo A. Prolactin pulsatility in polycystic ovarian disease. J Endocrinol Invest 1985; 8: 157–161
   PubMedGoogle Scholar
• Murdoch A P, Dunlop W, Kendall-Taylor P. Studies of prolactin in polycystic ovary syndrome. Clin Endocrinol (Oxf) 1986; 24: 175
   Google Scholar
• Bahceci M, Tuzcu A, Baheci S, Tuzcu S. Is hyperprolactinemia associated with insulin resistance in non-obese patients with polycystic ovary syndrome?. J Endocrinol Invest 2003; 26: 655–659
   PubMed Web of Science ®Google Scholar
• Lunde O. Hyperprolactinemia in polycystic ovary syndrome. Ann Chir Gynaecol 1981; 70: 197–201
   PubMedGoogle Scholar
• Luciano A A, Chapler F K, Sherman B M. Hyperprolactinemia in polycystic ovary syndrome. Fertil Steril 1984; 41: 719–725
   PubMed Web of Science ®Google Scholar
• Carmina E, Rosato F, Maggiore M, Gagliano A M, Indovina D, Janni A. Prolactin secretion in polycystic ovary syndrome (PCO): correlation with the steroid pattern. Acta Endocrinol (Copenh) 1984; 105: 99–104
   PubMedGoogle Scholar
• Wortsman J, Hirschowitz J S. Galactorrhoea and hyperprolactinemia during treatment of polycystic ovary syndrome. Obstet Gynecol 1980; 55: 460–463
   PubMedGoogle Scholar
• Duignan N M. Polycystic ovarian disease. Br J Obstet Gynaecol 1976; 83: 593–602
   PubMedGoogle Scholar
• Buvat J, Siame-Mourot C, Fourlinnie J C, Lamaire A, Buvat-Herbaut M, Hermand E. Androgens and prolactin levels in hirsute women with either polycystic ovaries or ‘borderline ovaries’. Fertil Steril 1982; 38: 695–700
   PubMed Web of Science ®Google Scholar
• Peillon F, Vincens M, Cesselin F, Doumith R, Mowszowicz I. Anovulatory cycles with an apparently normal level of blood prolactin. Treatment by bromocriptine. Nouv Presse Med 1979; 8: 3269–3270
   PubMedGoogle Scholar
• Alger M, Velasquez-Matute L, Mason M, Canales E S, Zarate A. Polycystic ovarian disease associated with hyperprolactinemia and defective response. Fertil Steril 1980; 34: 70–71
   PubMed Web of Science ®Google Scholar
• Corenblum B, Taylor P J. A rationale for the use of bromocriptine in patients with amenorrhea and normoprolactinemia. Fertil Steril 1980; 34: 239–241
   PubMedGoogle Scholar
• Corenblum B, Taylor P J. The hyperprolactinemic polycystic ovary syndrome may not be a distinct entity. Fertil Steril 1982; 38: 549–552
   PubMed Web of Science ®Google Scholar
• Buvat J, Buvat-Herbaut M, Marcolin G, Racadot A, Fourlinnie J C, Fossati P. Acute effects of bromocriptine on gonadotropin secretion in polycystic ovary syndrome. Fertil Steril 1985; 44: 356–360
   PubMedGoogle Scholar
• Shoupe D, Lobo R A. Prolactin response after gonadotropin-releasing hormone in the polycystic ovary syndrome. Fertil Steril 1985; 43: 549–553
   PubMedGoogle Scholar
• Falaschi P, Del Pozo E, Rocco A, Toscano V, Petrangeli E, Pompei P, Frajese G. Prolactin release in polycystic ovary. Obstet Gynecol 1980; 55: 579–582
   PubMed Web of Science ®Google Scholar
• Seppala M, Hirvonen E. Raised serum prolactin levels associated with hirsutism and amenorrhoea. Br Med J 1975; 4: 144–145
   PubMedGoogle Scholar
• Hamori M, Szendei G, Kovacs I, Somos P. The connection between hyperprolactinemia and polycystic ovary syndrome. Zentralbl Gynakol 1987; 109: 481–486
   PubMedGoogle Scholar
• Franks S, Murray M AF, Jequier A M, Steele S J, Nabarro J D, Jacobs H S. Incidence and significance of hyperprolactinemia in women with amenorrhoea. Clin Endocrinol (Oxf) 1975; 4: 597–607
   PubMed Web of Science ®Google Scholar
• Paoletti A M, Cagnacci A, Soldani R, Orru M, Ajossa S, Pittorra G, Mulas P, Melis G B. Evidence that an altered prolactin release is consequent to abnormal ovarian activity in polycystic ovary syndrome. Fertil Steril 1995; 64: 1094–1098
   PubMed Web of Science ®Google Scholar
• Vilar L, Naves L A, Casulari L A. Hiperprolactinemia – problemas no diagnóstico. Brasilia Med 2005; 42: 1–7
   Google Scholar
• Suliman A M, Smith T P, Gibney J, McKenna T J. Frequent misdiagnosis and mismanagement of hyperprolactinemia patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. Clin Chem 2003; 49: 1504–1509
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale H F. Macroprolactinemia in women presenting with hyperandrogenic symptoms: implications for the management of polycystic ovary syndrome. Fertil Steril 2004; 82: 1697–1699
   PubMedGoogle Scholar
• Forbes A P, Henneman P H, Griswold G C, Albright F. Syndrome characterized by galactorrhea, amenorrhea, and low urinary FSH: comparison with acromegaly and normal lactation. J Clin Endocrinol Metab 1954; 14: 265–271
   PubMed Web of Science ®Google Scholar
• Lavric M C. Galactorrhea and amenorrhea with polycystic ovaries. Del Castillo syndrome or polycystic ovarian disease. Am J Obstet Gynecol 1969; 104: 814–817
   PubMedGoogle Scholar
• Thorner M O, McNeilly A S, Hagan C, Besser G M. Long-term treatment of galactorrhoea and hypogonadism with bromocriptine. Br Med J 1974; 2: 419–422
   PubMed Web of Science ®Google Scholar
• Barnes R B, Mileikowsky G N, Cha K Y, Spencer C A, Lobo R A. Effects of dopamine and metoclopramide in polycystic ovary syndrome. J Clin Endocrinol Metab 1986; 63: 506–509
   PubMedGoogle Scholar
• Motta L DC, Motta L ACR, Gagliardi A RT. Bromocriptina na síndrome dos ovários policísticos: uma revisão. J Bras Ginecol 1989; 99: 177–181
   Google Scholar
• Crosignani P G, Reschini E, Lombroso G C, Arosio M, Peracchi M. Comparison of placebo and bromocriptine in the treatment of patients with normoprolactinaemic amenorrhoea. Br J Obstet Gynaecol 1978; 85: 773–775
   PubMedGoogle Scholar
• McBain J C, Popperell R J. Use of bromocriptine in unexplained infertility. Clin Reprod Fertil 1982; 1: 145–150
   PubMedGoogle Scholar
• Coelingh Bennink H J, van der Steeg H J. Failure of bromocriptine to restore the menstrual cycle in normoprolactinemic post-pill amenorrhea. Fertil Steril 1983; 39: 238–240
   PubMedGoogle Scholar
• Murdoch A P, McClean K G, Watson M J, Dunlop W, Kendall Taylor P. Treatment of hirsutism in polycystic ovary syndrome with bromocriptine. Br J Obstet Gynaecol 1987; 94: 358–365
   PubMedGoogle Scholar
• El Tabakh G H, Loutli A, Azab I, Rahman H A, Aleem F A, Southren A L. A controlled clinical trial for the effect of bromocriptine on the adrenal contribution in polycystic ovary syndrome. Acta Endocrinol (Copenh) 1987; 114: 161–165
   PubMedGoogle Scholar
• Spruce B A, Taylor P K, Dunlop W, Anderson A J, Watson M J, Cook D B, Gray C. The effect of bromocriptine in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1984; 20: 481–488
   PubMed Web of Science ®Google Scholar
• Dewailly D, Buvat J, Fourlinnie J C, Fessati P, Linquette M. Effects cliniques et biologiques de ládministracion prolongée de bromocriptine dans la maladie des ovaries polykystiques. Ann Endocrinol (Paris) 1982; 43: 134
   Google Scholar
• Thorner M O, Besser G M, Jones A, Dacie J, Jones A E. Bromocriptine treatment of female infertility: report of 13 pregnancies. Br Med J 1975; 4: 694–697
   PubMed Web of Science ®Google Scholar
• Ito M, Matsuura K, Aiko A, Matsui K, Yoshimura T, Okamura H. Successful treatment with bromocriptine of hypertension associated with polycystic ovarian disease. Acta Obstet Gynecol Scand 1987; 66: 279–282
   PubMed Web of Science ®Google Scholar
• Blum I, Bruhis S, Kaufman H. Clinical evaluation of the effects of combined treatment with bromocriptine and spironolactone in two women with the polycystic ovary syndrome. Fertil Steril 1981; 35: 629–633
   PubMedGoogle Scholar
• Blum I, Kaufman H, Merilus R, Rusecki Y, Chovers I. Successful treatment of polycystic ovary syndrome with spironolactone or bromocriptine. Obstet Gynecol 1981; 57: 661–665
   PubMedGoogle Scholar